Telix (ASX:TLX) share price slips despite priority review status

After rocketing 121% higher in November, the Telix Pharmaceuticals share price is down 2% today despite the company receiving priority review status.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is slipping today, down 2.5% in afternoon trading.

This comes despite the company reporting it had received priority review status from Australia's Therapeutic Goods Administration (TGA) for its prostate cancer imaging product, TLX591-CDx.

The priority review provides Telix with a fast-tracked timeframe of 150 working days for its product dossier review and approval.

It's possible this news was already factored into the share price. Telix shares soared 121% higher in the month of November, and the share price is up 152% year-to-date. By comparison, the S&P/ASX 200 Index (ASX: XJO) is flat since 2 January.

What does Telix Pharmaceuticals do?

Telix Pharmaceuticals is a biopharmaceutical company focused on developing diagnostic and therapeutic products via molecularly targeted radiation (MTR). Based in Melbourne, Telix has international operations in Belgium, Japan and the United States.

The company is currently developing a range of clinical-stage oncology products to address unmet medical needs involving prostate, kidney and brain cancers.

What does the priority review status mean for Telix shares?

Addressing the priority review status, Telix CEO Chris Behrenbruch said:

As an Australian headquartered company, we are especially delighted that the TGA has granted Priority Review for TLX591-CDx, bringing us one step closer to providing a commercially available prostate imaging agent to patients in our own backyard.

This is an important development for urologic oncology in Australia as a properly validated and commercially available product will ensure far greater patient access and confidence in the technology, currently only available on a limited basis under "special access" use from a relatively small number of academic nuclear medicine departments around the country.

The company reported that its Medical Services Advisory Committee (MSAC) application is already in progress. In a forward-looking statement, it revealed that it expects that MSAC approval and commercial availability of TLX591-CDx around May or June of 2021, provided it receives the TGA approval.

With prostate cancer killing 3,000 Aussie men each year (the second most common cause of cancer death), there are good reasons to hope Telix's imaging product is successful beyond any share price gains.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »

Father in the ocean with his daughters, symbolising passive income.
Dividend Investing

I'd spend $8k on these ASX 200 shares today to target a $6,102 annual passive income

I believe these ASX 200 shares will continue rewarding passive income investors for years to come.

Read more »

Three businesspeople leap high with the CBD in the background.
Share Market News

Boom! ASX 200 blasts to new record highs

ASX 200 investors just sent the benchmark index into uncharted territory.

Read more »